Samsung Biologics and Pfizer have struck a “long-term” deal worth more than $400m that will see the Korean company manufacture multiple biosimilars for Pfizer.
While details of the products involved were not revealed by the firms, Pfizer’s biosimilars portfolio covers several major products – including Zirabev (bevacizumab), Trazimera (trastuzumab), Ruxience (rituximab), Inflectra (infliximab) and Retacrit (epoetin alfa), as well as the Abrilada (adalimumab) biosimilar that will